The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Hyperlipidemia, Familial Combined

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Hyperlipidemia, Familial Combined


High impact information on Hyperlipidemia, Familial Combined


Chemical compound and disease context of Hyperlipidemia, Familial Combined


Biological context of Hyperlipidemia, Familial Combined


Anatomical context of Hyperlipidemia, Familial Combined


Gene context of Hyperlipidemia, Familial Combined


Analytical, diagnostic and therapeutic context of Hyperlipidemia, Familial Combined


  1. Familial dyslipidemic hypertension. Evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension. Williams, R.R., Hunt, S.C., Hopkins, P.N., Stults, B.M., Wu, L.L., Hasstedt, S.J., Barlow, G.K., Stephenson, S.H., Lalouel, J.M., Kuida, H. JAMA (1988) [Pubmed]
  2. Combination drug therapy for familial combined hyperlipidemia. East, C., Bilheimer, D.W., Grundy, S.M. Ann. Intern. Med. (1988) [Pubmed]
  3. Higher triglycerides, lower high-density lipoprotein cholesterol, and higher systolic blood pressure in lipoprotein lipase-deficient heterozygotes. A preliminary report. Sprecher, D.L., Harris, B.V., Stein, E.A., Bellet, P.S., Keilson, L.M., Simbartl, L.A. Circulation (1996) [Pubmed]
  4. Familial combined hyperlipidemia: upstream transcription factor 1 and beyond. Lee, J.C., Lusis, A.J., Pajukanta, P. Curr. Opin. Lipidol. (2006) [Pubmed]
  5. Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin. Blanco-Colio, L.M., Martín-Ventura, J.L., Sol, J.M., Díaz, C., Hernández, G., Egido, J. J. Am. Coll. Cardiol. (2004) [Pubmed]
  6. Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Pajukanta, P., Lilja, H.E., Sinsheimer, J.S., Cantor, R.M., Lusis, A.J., Gentile, M., Duan, X.J., Soro-Paavonen, A., Naukkarinen, J., Saarela, J., Laakso, M., Ehnholm, C., Taskinen, M.R., Peltonen, L. Nat. Genet. (2004) [Pubmed]
  7. Lipoprotein lipase modulates net secretory output of apolipoprotein B in vitro. A possible pathophysiologic explanation for familial combined hyperlipidemia. Williams, K.J., Petrie, K.A., Brocia, R.W., Swenson, T.L. J. Clin. Invest. (1991) [Pubmed]
  8. Identification of TNFRSF1B as a novel modifier gene in familial combined hyperlipidemia. Geurts, J.M., Janssen, R.G., van Greevenbroek, M.M., van der Kallen, C.J., Cantor, R.M., Bu, X., Aouizerat, B.E., Allayee, H., Rotter, J.I., de Bruin, T.W. Hum. Mol. Genet. (2000) [Pubmed]
  9. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. Merkel, M., Loeffler, B., Kluger, M., Fabig, N., Geppert, G., Pennacchio, L.A., Laatsch, A., Heeren, J. J. Biol. Chem. (2005) [Pubmed]
  10. Coexistence of familial dysalbuminemic hyperthyroxinemia with familial hypercholesterolemia and multiple lipoprotein type hyperlipidemia. Premachandra, B.N., Wolfe, B., Williams, I.K. Am. J. Med. (1988) [Pubmed]
  11. Impaired insulin-stimulated glucose oxidation and free fatty acid suppression in patients with familial combined hyperlipidemia: a precursor defect for dyslipidemia? Karjalainen, L., Pihlajamäki, J., Karhapää, P., Laakso, M. Arterioscler. Thromb. Vasc. Biol. (1998) [Pubmed]
  12. The redox status of coenzyme Q10 in total LDL as an indicator of in vivo oxidative modification. Studies on subjects with familial combined hyperlipidemia. de Rijke, Y.B., Bredie, S.J., Demacker, P.N., Vogelaar, J.M., Hak-Lemmers, H.L., Stalenhoef, A.F. Arterioscler. Thromb. Vasc. Biol. (1997) [Pubmed]
  13. Low plasma vitamin A concentrations in familial combined hyperlipidemia. Ribalta, J., LaVille, A.E., Girona, J., Vallvé, J.C., Masana, L. Clin. Chem. (1997) [Pubmed]
  14. Apolipoprotein A-II, genetic variation on chromosome 1q21-q24, and disease susceptibility. Martín-Campos, J.M., Escolà-Gil, J.C., Ribas, V., Blanco-Vaca, F. Curr. Opin. Lipidol. (2004) [Pubmed]
  15. Two novel apolipoprotein A-IV variants in individuals with familial combined hyperlipidemia and diminished levels of lipoprotein lipase activity. Deeb, S.S., Nevin, D.N., Iwasaki, L., Brunzell, J.D. Hum. Mutat. (1996) [Pubmed]
  16. Contribution of the hepatic lipase gene to the atherogenic lipoprotein phenotype in familial combined hyperlipidemia. Allayee, H., Dominguez, K.M., Aouizerat, B.E., Krauss, R.M., Rotter, J.I., Lu, J., Cantor, R.M., de Bruin, T.W., Lusis, A.J. J. Lipid Res. (2000) [Pubmed]
  17. Vitamin A is linked to the expression of the AI-CIII-AIV gene cluster in familial combined hyperlipidemia. Ribalta, J., Girona, J., Vallvé, J.C., La Ville, A.E., Heras, M., Masana, L. J. Lipid Res. (1999) [Pubmed]
  18. Regulatory mutations in the human lipoprotein lipase gene in patients with familial combined hyperlipidemia and coronary artery disease. Yang, W.S., Nevin, D.N., Iwasaki, L., Peng, R., Brown, B.G., Brunzell, J.D., Deeb, S.S. J. Lipid Res. (1996) [Pubmed]
  19. Postprandial adipose tissue lipoprotein lipase activity in primary hypertriglyceridemia. Goldberg, A.P., Chait, A., Brunzell, J.D. Metab. Clin. Exp. (1980) [Pubmed]
  20. TXNIP gene not associated with familial combined hyperlipidemia in the NHLBI Family Heart Study. Coon, H., Singh, N., Dunn, D., Eckfeldt, J.H., Province, M.A., Hopkins, P.N., Weiss, R., Hunt, S.C., Leppert, M.F. Atherosclerosis (2004) [Pubmed]
  21. Evidence against alterations in Lecithin:cholesterol acyltransferase (LCAT) activity in familial combined hyperlipidemia. Ribalta, J., La Ville, A.E., Vallvé, J.C., Girona, J., Masana, L. Atherosclerosis (1998) [Pubmed]
  22. Soluble receptors for tumor necrosis factor-alpha (TNF-R p55 and TNF-R p75) in familial combined hyperlipidemia. van Greevenbroek, M.M., van der Kallen, C.J., Geurts, J.M., Janssen, R.G., Buurman, W.A., de Bruin, T.W. Atherosclerosis (2000) [Pubmed]
  23. Identification of the PPARA locus on chromosome 22q13.3 as a modifier gene in familial combined hyperlipidemia. Eurlings, P.M., van der Kallen, C.J., Geurts, J.M., Flavell, D.M., de Bruin, T.W. Mol. Genet. Metab. (2002) [Pubmed]
  24. Common variants in the lipoprotein lipase gene, but not those in the insulin receptor substrate-1, the beta3-adrenergic receptor, and the intestinal fatty acid binding protein-2 genes, influence the lipid phenotypic expression in familial combined hyperlipidemia. Campagna, F., Montali, A., Baroni, M.G., Maria, A.T., Ricci, G., Antonini, R., Verna, R., Arca, M. Metab. Clin. Exp. (2002) [Pubmed]
  25. Comparison of gemfibrozil and clofibrate on serum lipids in familial combined hyperlipidemia. A randomized placebo-controlled, double-blind, crossover clinical trial. Rabkin, S.W., Hayden, M., Frohlich, J. Atherosclerosis (1988) [Pubmed]
WikiGenes - Universities